Patient experiences in follicular lymphoma research
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study asks people with follicular lymphoma to share their experiences during treatment. It's not testing a new drug—it's collecting information to help improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have been diagnosed with follicular lymphoma.
- You need a home internet connection to send regular updates.
- You cannot be pregnant or breastfeeding.
- You must not be taking any other experimental treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
This study looks at how follicular lymphoma cells change (“clonal evolution”) over time. It may help doctors understand disease behavior and guide better future treatments, especially when people may need treatment soon.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial tests an investigational pill (SHR2554) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if the pill can shrink the lymphoma and help control the disease.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.